EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 148 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 0.35 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $0 | – | 0 | -100.0% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 8 | -92.0% | 0.00% | – |
| Q3 2019 | $6,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q2 2019 | $6,000 | +20.0% | 100 | 0.0% | 0.00% | – |
| Q1 2019 | $5,000 | +25.0% | 100 | 0.0% | 0.00% | – |
| Q4 2018 | $4,000 | -60.0% | 100 | -33.3% | 0.00% | -100.0% |
| Q3 2018 | $10,000 | -50.0% | 150 | -40.0% | 0.00% | -50.0% |
| Q2 2018 | $20,000 | -71.8% | 250 | -81.5% | 0.00% | -66.7% |
| Q1 2018 | $71,000 | -38.3% | 1,350 | -37.2% | 0.01% | -40.0% |
| Q4 2017 | $115,000 | -86.2% | 2,150 | -84.6% | 0.01% | -89.5% |
| Q3 2017 | $833,000 | -13.6% | 13,975 | +14.3% | 0.10% | -24.6% |
| Q2 2017 | $964,000 | +45.2% | 12,225 | +52.8% | 0.13% | +31.2% |
| Q1 2017 | $664,000 | – | 8,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Hudson Executive Capital LP | 1,323,794 | $79,534,000 | 3.54% |
| Park West Asset Management LLC | 1,171,880 | $70,406,000 | 2.96% |
| Matarin Capital Management, LLC | 170,008 | $10,214,000 | 0.98% |
| Smith, Graham & Co., Investment Advisors, LP | 140,014 | $8,412,000 | 0.82% |
| Capital Impact Advisors, LLC | 33,725 | $2,026,000 | 0.71% |
| U S GLOBAL INVESTORS INC | 18,800 | $1,130,000 | 0.51% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 187,989 | $11,294,000 | 0.37% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,442,000 | 0.34% |
| GLOBEFLEX CAPITAL L P | 18,751 | $1,127,000 | 0.21% |
| Foundry Partners, LLC | 70,357 | $4,227,000 | 0.16% |